{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:17:41Z","timestamp":1792034261041,"version":"4.4.0"},"reference-count":93,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our understanding and management of atypical hemolytic uremic syndrome (aHUS) have dramatically improved in the last decade. aHUS has been established as a prototypic disease resulting from a dysregulation of the complement alternative C3 convertase. Subsequently, prospective nonrandomized studies and retrospective series have shown the efficacy of C5 blockade in the treatment of this devastating disease. C5 blockade has become the cornerstone of the treatment of aHUS. This therapeutic breakthrough has been dulled by persistent difficulties in the positive diagnosis of aHUS, and the latter remains, to date, a diagnosis by exclusion. Furthermore, the precise spectrum of complement-mediated renal thrombotic microangiopathy is still a matter of debate. Nevertheless, long-term management of aHUS is increasingly individualized and lifelong C5 blockade is no longer a paradigm that applies to all patients with this disease. The potential benefit of complement blockade in other forms of HUS, notably secondary HUS, remains uncertain.<\/jats:p>","DOI":"10.1182\/blood.2022017860","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T21:07:46Z","timestamp":1667423266000},"page":"984-995","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":88,"title":["How I diagnose and treat atypical hemolytic uremic syndrome"],"prefix":"10.1182","volume":"141","author":[{"given":"Fadi","family":"Fakhouri","sequence":"first","affiliation":[{"name":"1Department of Medicine, Service of Nephrology and Hypertension, Lausanne University Hospital and Universit\u00e9 de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Schwotzer","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Service of Nephrology and Hypertension, Lausanne University Hospital and Universit\u00e9 de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-8528","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[{"name":"2Laboratory of Immunology, Paris University, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges-Pompidou, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10095","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"issue":"10","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"68","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"2016","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"issue":"18","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.2021012752","article-title":"COVID-19 as a potential trigger of complement-mediated atypical HUS","volume":"138","author":"El Sissy","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2215\/CJN.05830518","article-title":"Complement gene variants and Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: retrospective genetic and clinical study","volume":"14","author":"Fremeaux-Bacchi","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/JCM.03288-14","article-title":"Evaluation of enzyme immunoassays and real-time PCR for detecting Shiga toxin-producing Escherichia coli in Southern Alberta, Canada","volume":"53","author":"Chui","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"9997","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00077-X","article-title":"Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognised?","volume":"386","author":"George","year":"2015","journal-title":"Lancet"},{"issue":"9997","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(15)00076-8","article-title":"Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency","volume":"386","author":"Grange","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12882-020-01748-2","article-title":"Cobalamin c deficiency associated with antifactor H antibody-associated hemolytic uremic syndrome in a young adult","volume":"21","author":"Philipponnet","year":"2020","journal-title":"BMC Nephrol"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13023-022-02179-y","article-title":"Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists","volume":"17","author":"Kalantari","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.ajkd.2021.12.014","article-title":"Complement activation and thrombotic microangiopathy associated with monoclonal gammopathy: a national French case series","volume":"80","author":"Martins","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"780107","DOI":"10.3389\/fimmu.2021.780107","article-title":"Thrombotic microangiopathy, an unusual form of monoclonal gammopathy of renal significance: report of 3 cases and literature review","volume":"12","author":"Filippone","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.25569","article-title":"Monoclonal gammopathy-associated thrombotic microangiopathy","volume":"94","author":"Yui","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"issue":"21","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"100945","DOI":"10.1016\/j.blre.2022.100945","article-title":"Advances in the management of TTP","author":"Subhan","year":"2022","journal-title":"Blood Rev"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"2023030216272586700_","first-page":"648","article-title":"Urine protein\/creatinine ratio in thrombotic microangiopathies: a simple test to facilitate thrombotic thrombocytopenic purpura and hemolytic and uremic syndrome diagnosis","volume":"11","author":"Burguet","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ekir.2021.11.009","article-title":"Proteinuria increases the PLASMIC and French scores performance to predict thrombotic thrombocytopenic purpura in patients with thrombotic microangiopathy syndrome","volume":"7","author":"Fage","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/trf.16188","article-title":"Reduced sensitivity of PLASMIC and French scores for\u00a0the diagnosis of thrombotic thrombocytopenic purpura in older individuals","volume":"61","author":"Liu","year":"2021","journal-title":"Transfusion"},{"issue":"4","key":"2023030216272586700_","first-page":"1271","article-title":"Thrombotic microangiopathy with mild renal involvement and profound thrombocytopenia: not all roads lead to thrombotic thrombocytopenic purpura","volume":"35","author":"Milon","year":"2022","journal-title":"J\u00a0Nephrol"},{"issue":"19","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","article-title":"Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort","volume":"37","author":"Rubin","year":"2019","journal-title":"J\u00a0Hypertens"},{"issue":"11","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/01.hjh.0000249710.21146.38","article-title":"Ethnic disparities in the incidence, presentation and complications of malignant hypertension","volume":"24","author":"van den Born","year":"2006","journal-title":"J\u00a0Hypertens"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ehjcvp\/pvy032","article-title":"ESC Council on hypertension position document on the management of hypertensive emergencies","volume":"5","author":"van den Born","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ajh.2009.153","article-title":"Improving survival of malignant hypertension patients over 40 years","volume":"22","author":"Lane","year":"2009","journal-title":"Am J Hypertens"},{"issue":"8","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00004872-199508000-00013","article-title":"Complications and survival of 315 patients with malignant-phase hypertension","volume":"13","author":"Lip","year":"1995","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/HJH.0000000000001446","article-title":"Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry","volume":"35","author":"Shantsila","year":"2017","journal-title":"J\u00a0Hypertens"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int"},{"issue":"8","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"issue":"6","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome","volume":"65","author":"Wetzels","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"18","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical haemolytic uremic syndrome: a prospective multicentric study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023030216272586700_","first-page":"279","article-title":"Haemoglobinuria for the early identification of aHUS relapse: data from the ItalKId-HUS Network","volume":"35","author":"Brambilla","year":"2022","journal-title":"J\u00a0Nephrol"},{"issue":"6","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"issue":"9","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2023030216272586700_","first-page":"gin\/33.4.14","article-title":"Efficacy of eculizumab in a case of pregnancy-associated aHUS [in Italian]","volume":"33","author":"Cravero","year":"2016","journal-title":"G\u00a0Ital\u00a0Nefrol"},{"issue":"8","key":"2023030216272586700_","first-page":"1421","article-title":"Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome","volume":"93","author":"Canigral","year":"2014","journal-title":"Ann Hematol"},{"issue":"5","key":"2023030216272586700_","first-page":"641","article-title":"Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management","volume":"28","author":"De Sousa Amorim","year":"2015","journal-title":"J\u00a0Nephrol"},{"issue":"suppl 1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nep.12938","article-title":"Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab","volume":"22","author":"Gately","year":"2017","journal-title":"Nephrology"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int"},{"issue":"21","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood.V124.21.5019.5019","article-title":"Pregnancy-associated atypical hemolytic uremic syndrome (aHUS), treated with eculizumab","volume":"124","author":"Mandala","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1055\/s-0036-1579539","article-title":"Pregnancy-associated atypical hemolytic-uremic syndrome","volume":"6","author":"Saad","year":"2016","journal-title":"AJP Rep"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1753495X17704563","article-title":"Pregnancy-induced atypical haemolytic uremic syndrome: a new era with eculizumab","volume":"11","author":"Shanmugalingam","year":"2018","journal-title":"Obstet Med"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Socie","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","article-title":"Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab","volume":"31","author":"Servais","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518171","article-title":"Pregnancy in women with atypical hemolytic uremic syndrome","volume":"146","author":"Rondeau","year":"2022","journal-title":"Nephron"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10875-015-0137-5","article-title":"Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe","volume":"35","author":"Turley","year":"2015","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12879-019-4146-5","article-title":"Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017)","volume":"19","author":"Ladhani","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"8","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jix143","article-title":"Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies","volume":"215","author":"Rosain","year":"2017","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"2023030216272586700_","first-page":"298","article-title":"Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab","volume":"35","author":"Gackler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"e20174250","DOI":"10.1542\/peds.2017-4250","article-title":"Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function","volume":"142","author":"Martinon-Torres","year":"2018","journal-title":"Pediatrics"},{"issue":"15","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/bloodadvances.2020002497","article-title":"Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients","volume":"4","author":"Langereis","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2018.03.087","article-title":"A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab","volume":"36","author":"Reher","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"e20162452","DOI":"10.1542\/peds.2016-2452","article-title":"Meningococcal B vaccine failure with a penicillin-resistant strain in a young adult on long-term eculizumab","volume":"140","author":"Parikh","year":"2017","journal-title":"Pediatrics"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciy958","article-title":"Disseminated gonococcal infections in patients receiving eculizumab: a case series","volume":"69","author":"Crew","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10875-022-01213-9","article-title":"Clinical outcome and underlying genetic cause of functional terminal complement pathway deficiencies in a multicenter UK cohort","volume":"42","author":"Shears","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"issue":"5","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2020081224","article-title":"IgM autoantibodies to complement factor H in atypical hemolytic uremic syndrome","volume":"32","author":"Cugno","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2015.03.039","article-title":"Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgA\u03bb antibody","volume":"66","author":"Rigothier","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"issue":"11","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new\u00a0paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"3","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.kint.2019.01.009","article-title":"Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation","volume":"96","author":"Ueda","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"2023030216272586700_","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJMc2112090","article-title":"Ultrarapid nanopore genome sequencing in a critical care setting","volume":"386","author":"Gorzynski","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/9\/984\/2036347\/blood_bld-2022-017860-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/9\/984\/2036347\/blood_bld-2022-017860-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:56:54Z","timestamp":1678496214000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/9\/984\/486972\/How-I-diagnose-and-treat-atypical-hemolytic-uremic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017860","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}